Ng, KW;
Faulkner, N;
Cornish, GH;
Rosa, A;
Harvey, R;
Hussain, S;
Ulferts, R;
... Kassiotis, G; + view all
(2020)
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.
Science
, Article eabe1107. 10.1126/science.abe1107.
(In press).
Preview |
Text (Article)
Ng et al2020Article_Pre-Edit 5.pdf - Accepted Version Download (1MB) | Preview |
Preview |
Text (Supplementary materials)
Ng et alScience 2020_Pre-Edit 2.3Suppl.pdf - Accepted Version Download (3MB) | Preview |
Abstract
Zoonotic introduction of novel coronaviruses may encounter preexisting immunity in humans. Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, we detect preexisting humoral immunity. SARS-CoV-2 spike glycoprotein (S)-reactive antibodies were detectable by a flow cytometry-based method in SARS-CoV-2-uninfected individuals and were particularly prevalent in children and adolescents. They were predominantly of the IgG class and targeted the S2 subunit. By contrast, SARS-CoV-2 infection induced higher titers of SARS-CoV-2 S-reactive IgG antibodies, targeting both the S1 and S2 subunits, and concomitant IgM and IgA antibodies, lasting throughout the observation period. Notably, SARS-CoV-2-uninfected donor sera exhibited specific neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes. Distinguishing preexisting and de novo immunity will be critical for our understanding of susceptibility to and the natural course of SARS-CoV-2 infection.
Archive Staff Only
 |
View Item |
